Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SteelPower male enhancement reviews, scam searches, complaints, ingredients, price, and refund policy — what men need to know.
-
Seville, ANDALUCIA, May 06, 2026 (GLOBE NEWSWIRE) -- EuroAmerican Financial Advisors (EAFA) is drawing attention to a growing issue affecting Americans who invest through European financial...
-
NEW ORLEANS, May 06, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 26, 2026 to file lead plaintiff applications in...
-
NEW ORLEANS, May 06, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 26, 2026 to file lead plaintiff applications in a...
-
NEW ORLEANS, May 06, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 22, 2026 to file lead plaintiff applications in a...
-
NEW ORLEANS, May 06, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 26, 2026 to file lead plaintiff applications in a...
-
SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,859,155 shares of its...
-
NEW ORLEANS, May 06, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 18, 2026 to file lead plaintiff applications in a...
-
NEW ORLEANS, May 06, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 11, 2026 to file lead plaintiff applications in a...
-
The IND approval marks another milestone in our solid tumor pipeline and validates the huge drug development potential of our ADC platform.